Author:
Chang Lin-lin,Li Yue-kang,Zhao Chen-xi,Zeng Chen-ming,Ge Fu-jing,Du Jia-min,Zhang Wen-zhou,Lu Pei-hua,He Qiao-jun,Zhu Hong,Yang Bo
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference60 articles.
1. Dhagat U, Endo S, Sumii R, Hara A, El-Kabbani O. Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid. J Med Chem. 2008;51:4844–8.
2. Ohta T, Ishikura S, Shintani S, Usami N, Hara A. Kinetic alteration of a human dihydrodiol/3alpha-hydroxysteroid dehydrogenase isoenzyme, AKR1C4, by replacement of histidine-216 with tyrosine or phenylalanine. Biochem J. 2000;352:685–91.
3. Zhou C, Shen GW, Yang F, Duan JL, Wu Z, Yang MQ, et al. Loss of AKR1C1 is a good prognostic factor in advanced NPC cases and increases chemosensitivity to cisplatin in NPC cells. J Cell Mol Med. 2020;24:6438–47.
4. Zhu H, Chang LL, Yan FJ, Hu Y, Zeng CM, Zhou TY, et al. AKR1C1 activates STAT3 to promote the metastasis of non-small cell lung cancer. Theranostics. 2018;8:676–92.
5. Tian H, Li X, Jiang WL, Lv CT, Sun WZ, Huang CG, et al. High expression of AKR1C1 is associated with proliferation and migration of small-cell lung cancer cells. Lung Cancer. 2016;7:53–61.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献